Two-drugs regimens did not influence total HIV-1 DNA in people living with HIV [0.03%]
两种药物方案不会影响HIV携带者的总HIV-1DNA水平
Gabriele Cavazza,Alice Nava,Elena Nicolini et al.
Gabriele Cavazza et al.
BackgroundQuantitative HIV-1 DNA (qDNA) is a biomarker of the viral reservoir. We evaluated whether two-drug regimens (2DRs) maintain qDNA values comparable to those of three-drug therapies (3DRs).Materials and methodsWe collected data from...
Use of short-course oral amenamevir (helicase-primase inhibitor) for the treatment of thymidine analogue-resistant herpes simplex lesions [0.03%]
用于胸腺嘧啶类似物耐药单纯疱疹病灶治疗的短程口服氨菲名韦（解旋酶-原酸酶抑制剂）
Martine Altidor,Claire Richardson,Chitra Babu et al.
Martine Altidor et al.
Herpes simplex virus (HSV) resistance is rare, but incidence is rising. Managing resistant HSV phenotypes in individuals living with human immunodeficiency virus (HIV) poses an increasing challenge. Here, we present two (2) cases where a sh...
Kim Begley,Don Smith,Handan Wand et al.
Kim Begley et al.
BackgroundBiopsychosocial comorbidities are common in chronic illnesses like HIV, often resulting in complex clinical presentations. The Clinical Complexity Rating Scale for HIV (CCRS-HIV) was developed to identify these factors. This study...
Effectiveness and safety of dolutegravir/lamivudine/abacavir versus bictegravir/emtricitabine/tenofovir alafenamide as first-line regimens in real-world settings (MICTLAN study) [0.03%]
多替拉韦/拉米夫定/阿巴卡韦与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为一线方案的有效性和安全性：米克特兰研究
José Antonio Mata-Marín,Mara Soraya Rodríguez-Evaristo,Ana Luz Cano-Díaz et al.
José Antonio Mata-Marín et al.
BackgroundIntegrase strand transfer inhibitor (INSTI)-based regimens, such as dolutegravir/lamivudine/abacavir (DTG/3TC/ABC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), are recommended as first-line antiretroviral the...
Prevalence and clinical characteristics of individuals presenting with AIDS and late HIV diagnosis in Egypt [0.03%]
埃及AIDS患者的确诊时间及临床特征研究
Lamiaa Al Sehemy,Rahma Mohamed,Ammar Hatem et al.
Lamiaa Al Sehemy et al.
BackgroundEgypt has fastest-growing HIV rate in the Middle East and North Africa. This study aimed to determine the prevalence of late diagnosis (LD) and examine the associated epidemiological and clinical characteristics in a cohort of Egy...
Telma R de Mônaco E Magalhães,Adriana Bittencourt Campaner,Marco Antonio Castro et al.
Telma R de Mônaco E Magalhães et al.
Background: Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection (STI) worldwide, often asymptomatic in women and associated with severe reproductive complications. In Brazil, population-based screening is no...
Severe flare of genital warts after intralesional nonvalent HPV vaccine and development of multiple nodules at the sites of injection [0.03%]
九价人乳头瘤病毒疫苗局部注射部位的注射后结节及生殖器尖锐湿疣重度复发病例报告
Christina Stefanaki,Gerasimos Karousos,Sotirios Sachanas
Christina Stefanaki
Few effective treatments exists for the elimination of persistant genital warts and recurrences are common. We report the cases of two healthy HIV negative and immunocompetent men with a longstanding history of refractory to treatment and r...
A demographic analysis of Latin American sexual and reproductive health service users [0.03%]
拉丁美洲性与生殖健康服务使用者的人口统计分析
Taiana Silva Carvalho,Jose Eduardo de Carvalho Peres,Dwayne Hunt et al.
Taiana Silva Carvalho et al.
High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV [0.03%]
新近感染人类免疫缺陷病毒(HIV)患者的高水平多重耐药病毒株挑战治疗方案
Theodore R Miller,Cristina Gruta,Raymund Sison et al.
Theodore R Miller et al.
A 19 year old man was diagnosed newly acquired HIV and prescribed bictegravir/emtricitabine/tenofovir alafenamide at his initial visit for HIV care. The genotype results from that initial visit returned two weeks later, showing high-level m...
Correlates of HIV pre-exposure prophylaxis (PrEP) uptake among female sex workers in northern Nigeria [0.03%]
尼日利亚北部性工作者使用口服预防性治疗药物的相关因素分析
Abubakar A Sadiq,Zubairu Iliyasu,Ganiyat F Rasheed et al.
Abubakar A Sadiq et al.
BackgroundFemale sex workers (FSWs) face a disproportionately high risk of HIV acquisition, yet uptake of pre-exposure prophylaxis (PrEP) remains low in many settings. We examined PrEP awareness, utilization, and adherence, and identified p...